Rate of freeze alters the immunologic response after cryoablation of breast cancer
- PMID: 20033323
- DOI: 10.1245/s10434-009-0846-1
Rate of freeze alters the immunologic response after cryoablation of breast cancer
Abstract
Background: Cryoablation has garnered significant interest as a treatment for solid tumors including breast cancer for both its local effects and potential in stimulating an antitumor immune response. We sought to examine the impact that variances in technique might have on the immune response and examine the mechanism by which cryoablation may stimulate an antitumor immune response.
Materials and methods: Balb/c mice with established 4T1 mammary carcinomas were treated by cryoablation at either a high rate of freeze or low rate of freeze, or by surgical excision, after spontaneous metastases occurred. Tumor-draining lymph nodes (TDLN) were excised at 1 week for EliSPOT assay and immunophenotyping. Mice were followed after treatment for enumeration of pulmonary metastases and survival.
Results: Compared with surgical excision, cryoablation using a high freeze rate resulted in a significant increase in tumor-specific T cells in the TDLN, a reduction in pulmonary metastases, and improved survival. However, cryoablation using a low freeze rate resulted in an increase in regulatory T cells, a significant increase in pulmonary metastases, and decreased survival.
Conclusions: Cryoablation of breast cancer in mice can generate a tumor-specific immune response that can eradicate systemic micrometastases and improve outcome compared with surgical excision; however, the technique used to freeze the tissue may alter the immune response from stimulatory to suppressive.
Similar articles
-
Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor.Cryobiology. 2006 Dec;53(3):360-6. doi: 10.1016/j.cryobiol.2006.07.004. Epub 2006 Sep 14. Cryobiology. 2006. PMID: 16973145
-
Immunologic response to cryoablation of breast cancer.Breast Cancer Res Treat. 2005 Mar;90(1):97-104. doi: 10.1007/s10549-004-3289-1. Breast Cancer Res Treat. 2005. PMID: 15770533
-
Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.Cancer Res. 2002 Oct 15;62(20):5727-35. Cancer Res. 2002. PMID: 12384531
-
Cryosurgery of breast cancer.Gland Surg. 2012 Aug;1(2):111-8. doi: 10.3978/j.issn.2227-684X.2012.08.01. Gland Surg. 2012. PMID: 25083433 Free PMC article. Review.
-
Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy.Radiol Imaging Cancer. 2021 Feb 26;3(2):e200134. doi: 10.1148/rycan.2021200134. eCollection 2021 Mar. Radiol Imaging Cancer. 2021. PMID: 33817653 Free PMC article. Review.
Cited by
-
Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy.Curr Oncol Rep. 2021 Apr 17;23(6):68. doi: 10.1007/s11912-021-01057-3. Curr Oncol Rep. 2021. PMID: 33864144 Free PMC article. Review.
-
Progress in the cryoablation and cryoimmunotherapy for tumor.Front Immunol. 2023 Jan 25;14:1094009. doi: 10.3389/fimmu.2023.1094009. eCollection 2023. Front Immunol. 2023. PMID: 36761748 Free PMC article. Review.
-
Thermal ablation of tumours: biological mechanisms and advances in therapy.Nat Rev Cancer. 2014 Mar;14(3):199-208. doi: 10.1038/nrc3672. Nat Rev Cancer. 2014. PMID: 24561446 Review.
-
Minimally invasive surgical management of benign breast lesions.Gland Surg. 2014 May;3(2):142-8. doi: 10.3978/j.issn.2227-684X.2014.04.01. Gland Surg. 2014. PMID: 25083508 Free PMC article. Review.
-
Postablation Immune Microenvironment: Synergy between Interventional Oncology and Immuno-oncology.Semin Intervent Radiol. 2019 Oct;36(4):334-342. doi: 10.1055/s-0039-1696704. Epub 2019 Oct 31. Semin Intervent Radiol. 2019. PMID: 31680725 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical